Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Inavolisib plus palbociclib and fulvestrant reduced the risk of progression or death in HR+/HER2– PIK3CA-mutated advanced or metastatic breast cancer.

Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Videos

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV. 

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond

Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.

Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.

An Introduction to Biomarker Testing in Metastatic Colorectal Cancer 

An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.

Clinical Trial Review: MOUNTAINEER

Clinical insights regarding the design, patient population, and overall aims of the ongoing phase 3 clinical trial MOUNTAINEER-03.

MOUNTAINEER-03 Clinical Trial Study Design and Implications

Discussion centered around emerging treatment options for patients with HER2+ mCRC, including trastuzumab deruxtucan.

Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer

Dr Tanios S. Bekaii-Saab closes the discussion with key unmet needs in the mCRC treatment landscape. 

The Future of the Metastatic Colorectal Cancer Treatment Landscape

The Future of the Metastatic Colorectal Cancer Treatment Landscape

EP: 1.An Introduction to Biomarker Testing in Metastatic Colorectal Cancer

EP: 2.Clinical Trial Review: MOUNTAINEER

EP: 3.MOUNTAINEER-03 Clinical Trial Study Design and Implications

EP: 4.Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer

EP: 5.The Future of the Metastatic Colorectal Cancer Treatment Landscape

Latest Conference Coverage